# TRACE Q20-lly-margins-next-year  session=sess_42cf31c64c13

## 0. LLM input at turn start (reconstructed from code + question; deterministic)

### system prompt (meta_agent._SYSTEM, verbatim)
```
You are the analyst for a portfolio risk & issuer-intelligence desk. The analysis is your job: take the question apart, decide what to look at and what to compare, get the figures, and say what the evidence shows and what it means for the question asked — its implication for this book and what would change your reading. describe(subject) is where you look first: what the desk holds about a ticker, a portfolio, a run or a scenario, what is NOT held and why, and the methods and procedures that apply; a book question starts at describe() with no subject, which lists the portfolios and their ids — never guess an id.

Figures come from ONE tool: run(program). Write the whole computation as one program — the reads, the methods over lists of subjects, the arithmetic, the ranking, the change, the scenario — and every node comes back typed, dated and on the ledger as a fact (f_…). A superlative rests on a rank node; a change on yoy/qoq or two readings; the prior run is run(which='prev'); a name in a program is a variable, never a measure. A node that refuses says why; fix the program, do not guess. Filing text is read_filings; what the filings cannot hold is search_web; work that is not ready is start.

The answer is CLAIMS and PROSE (respond). Each figure you state is a claim with a relation its facts must fit — level, change, ratio, rank, room, absent, quote, series, table — and the prose writes {cN} where the figure goes. Write {cN} in the prose where claim cN's figure goes; the reader sees the fact's value with its identity. A number you write out yourself is accepted only when the ledger accounts for it — a fact's value, its date or window, a quoted passage's words, or a figure from the user's own question. A figure you worked out yourself has no fact: run a program for it. A figure the desk does not hold is an absence fact: claim it as absent and say why (not filed; not held as a figure; no method) — never a nearby figure wearing the asked-for name, never an estimate.

Finish every turn by calling respond. If respond refuses, it names the claim or the number and the reason: fix that claim, run the program that produces the figure, or drop it.
```

### pushed domain knowledge (skill.match_domains -> ['issuer_outlook_boundary', 'issuer_profitability']; verbatim push_text)
```
DOMAIN issuer_outlook_boundary — what the desk will and will not say about the future, and what the issuer's own filings say would move it
this desk: the desk does not forecast; asked for a number about the future it says so and gives what the filings say would move the figure the one question for management is built from the line the numbers show moving, not from the narrative
compare: management's stated drivers against the lines that have actually moved the same statement across filings for consistency
close: the drivers, each with the line it shows in and that line's recent direction one question, phrased so the answer would be a number the filings do not yet hold
absent here: a projected figure is absent by policy, not by data; say the policy
program — the recent direction of the lines the narrative names:
{"let":[["rev",{"fn":"fundamentals","ticker":"<T>","metric":"revenue","months":12,"last_n":5}],["rev_g",{"fn":"yoy","of":"$rev"}]]}

DOMAIN issuer_profitability — how profitable the issuer is, at which line, against whom, and whether it is mix, pricing or cost
this desk: the margins name which revenue line they divided by; issuers that report revenue under two tags are read on the one the registry chose an ordering is a computation with a row: a superlative in the answer rests on the ranking, not on reading the figures by eye
compare: level and slope for each name over the same windows: who is higher, whose is moving gross against operating margin to separate cost of goods from overhead; net against operating to isolate interest, tax and non-operating items a ranking on one measure against the same ranking on another, when the question asks whether it holds
close: a sentence for the level, a sentence for the slope, and what that implies for the question asked name the runner-up and the gap when a name is called the best
absent here: an issuer whose input is not filed on a line is unmeasured on that line and stays in the comparison as such, never dropped
program — margins across names, then the ordering:
{"let":[["gm",{"fn":"method","name":"gross_margin","subject":["<T1>","<T2>"]}],["om",{"fn":"method","name":"operating_margin","subject":["<T1>","<T2>"]}],["nm",{"fn":"method","name":"net_margin","subject":["<T1>","<T2>"]}],["best_gm",{"fn":"rank","of":"$gm","direction":"highest"}],["ret_capital",{"fn":"method","name":"roic","subject":["<T1>","<T2>"]}],["best_roic",{"fn":"rank","of":"$ret_capital","direction":"highest"}]]}
program — a margin over its own history:
{"let":[["gm",{"fn":"method","name":"gross_margin","subject":"<T>","params":{"last_n":8}}],["gm_change",{"fn":"yoy","of":"$gm"}]]}
program — DuPont:
{"let":[["ret_equity",{"fn":"method","name":"roe","subject":"<T>"}],["nm",{"fn":"method","name":"net_margin","subject":"<T>"}],["turn",{"fn":"method","name":"asset_turnover","subject":"<T>"}],["lev",{"fn":"method","name":"equity_multiplier","subject":"<T>"}]]}
```

### user message
```
Will Lilly's margins keep expanding next year?
```

### tools offered: see trace/tools_schema_meta_face.json (identical for every session; respond's description carries the claims grammar)


## 1. Step chain (agent_steps, seq order). LLM OUT = the tool calls that follow an llm_call row.


---
### LLM CALL #1  (seq 1)  actual prompt_tokens=4360 completion_tokens=24  -> gpt-5.4-mini-2026-03-17: 1 tool call
(assistant text alongside the tool calls is NOT persisted; only the tool calls below are)

#### LLM OUT -> TOOL CALL  seq 2  `describe`  status=completed  17ms
LLM wrote (args, full):
```json
{
 "expand": "issuer_outlook_boundary",
 "subject": "LLY"
}
```
TOOL summary: `keys: subject, kind, domain, question, asked_as, evidence, this_desk, compare`
TOOL -> LLM: no facts recorded on this step (a catalogue/describe payload or a refusal; the note JSON is not persisted)

---
### LLM CALL #2  (seq 3)  actual prompt_tokens=5581 completion_tokens=33  -> gpt-5.4-mini-2026-03-17: 1 tool call
(assistant text alongside the tool calls is NOT persisted; only the tool calls below are)

#### LLM OUT -> TOOL CALL  seq 4  `read_filings`  status=completed  8ms
LLM wrote (args, full):
```json
{
 "k": 5,
 "item": "7",
 "ticker": "LLY",
 "form_type": "10-K"
}
```
TOOL summary: `keys: ticker, item_code, title, citation, fact, facts`
TOOL -> LLM `facts` block (1 facts; EXACT JSON the model read, rebuilt from evidence_refs via facts.block_for_model):
```json
{
 "columns": [
  "id",
  "kind",
  "subject",
  "measure",
  "unit",
  "value",
  "as_of",
  "window",
  "params",
  "sources"
 ],
 "rows": [
  [
   "f_7de4683d6b88",
   "passage",
   "LLY",
   "10-K Item 7",
   null,
   {
    "text": "Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with Item 8, \"Financial Statements and Supplementary Data.\" Certain statements in this Item 7 constitute forward-looking statements. Various risks and uncertainties, including those discussed in \"Forward-Looking Statements\" and Item 1A, \"Risk Factors,\" may cause our actual results, financial position, and cash generated from operations to differ from these forward-looking statements.\n\nEXECUTIVE OVERVIEW\n\nThis section provides an overview of our financial results, our clinical development pipeline, and other matters affecting our company and industry. \n\nFinancial Results\n\nThe following table summarizes certain financial information:\n\nYear Ended December 31,\n\nPercent Change\n\n20252024\n\nRevenue$65,179 $45,043 45\n\nNet income20,640 10,590 95\n\nEarnings per share - diluted22.95 11.71 96\n\nRevenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound.\n\nNet income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.\n\nSee \"Results of Operations\" for additional information.\n\n43\n\nClinical Development Pipeline\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines. \n\nThe following select new molecular entities (NMEs) and new indication line extension (NILEX) products are currently in clinical trials or have been submitted for regulatory review or have recently received regulatory approval in the U.S., European Union (EU), or Japan. The table reflects the status of these NMEs and NILEX products, up to the time of the filing of this Annual Report on Form 10-K:\n\nCompoundIndication/Study\n\nStatus Developments\n\nCardiometabolic Health\n\nTirzepatide (Mounjaro, Zepbound)Heart failure with preserved ejection fractionApproved\n\nApproved in the EU.\n\nPediatric and adolescent type 2 diabetesApprovedApproved in the U.S. and the EU.\n\nCardiovascular outcomes in type 2 diabetesSubmittedSubmitted in the U.S.\n\nMetabolic dysfunction-associated steatotic liver diseasePhase 3Phase 3 trial was initiated.\n\nMorbidity and mortality in obesityPhase 3Phase 3 trial is ongoing.\n\nType 1 diabetesPhase 3Phase 3 trials were initiated.\n\nInsulin efsitora alfa\n\nType 2 diabetesSubmittedSubmitted in the U.S., the EU, and Japan.\n\nOrforglipronObesity(1)\n\nSubmittedSubmitted in the U.S., the EU, and Japan.\n\nType 2 diabetesSubmittedSubmitted in the EU. Phase 3 trials are ongoing.\n\nCardiovascular outcomes Phase 3Phase 3 trial was initiated.\n\nHypertensionPhase 3Phase 3 trial was initiated.\n\nObstructive Sleep Apnea (OSA)Phase 3Phase 3 trials are ongoing.\n\nOsteoarthritis painPhase 3Phase 3 trial was initiated.\n\nPeripheral artery diseasePhase 3Phase 3 trial was initiated.\n\nStress urinary incontinencePhase 3Phase 3 trial was initiated.\n\nEloralintideObesityPhase 3Phase 3 trial was initiated.\n\nLepodisiranAtherosclerotic cardiovascular diseasePhase 3Phase 3 trial is ongoing.\n\nMuvalaplinAtherosclerotic cardiovascular diseasePhase 3Phase 3 trial was initiated.\n\nRetatrutideCardiovascular / renal outcomesPhase 3Phase 3 trials are ongoing.\n\nChronic low back painPhase 3Phase 3 trial was initiated.\n\nMetabolic dysfunction-associated steatotic liver diseasePhase 3Phase 3 trial was initiated.\n\nObesity, osteoarthritis, OSAPhase 3Phase 3 trial met all primary and key secondary endpoints. Phase 3 trials are ongoing.\n\nType 2 diabetesPhase 3Phase 3 trials are ongoing.\n\n44\n\nCompoundIndication/Study\n\nStatus Developments\n\nImmunology\n\nMirikizumab (Omvoh)Crohn's diseaseApprovedApproved in the U.S., the EU, and Japan.\n\nLebrikizumab(2)\n\nAR (perennial allergens)Phase 3Phase 3 trial is ongoing.\n\nCRSwNPPhase 3Phase 3 trial is ongoing.\n\nNeuroscience\n\nDonanemab (Kisunla)Early Alzheimer's diseaseApprovedApproved in the U.S., the EU, and Japan.\n\nPre-clinical Alzheimer's diseasePhase 3Phase 3 trial is ongoing.\n\nBrenipatideAlcohol use disorderPhase 3Phase 3 trial was initiated.\n\nIxo-vecWet age‑related macular degenerationPhase 3Acquired in the acquisition of Adverum Biotechnologies, Inc. Phase 3 trial is ongoing.\n\nRemternetugPre-clinical/MCI Alzheimer's diseasePhase 3Phase 3 trials are ongoing.\n\nOncology\n\nImlunestrant (Inluriyo)ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerApprovedApproved in the U.S., the EU, and Japan.\n\nAdjuvant breast cancerPhase 3Phase 3 trial is ongoing.\n\nPirtobrutinib\n\n(Jaypirca)\n\nChronic lymphocytic leukemiaApprovedFull approval in the U.S., the EU, and Japan.\n\nOlomorasib(3)\n\n1L KRAS G12C+ NSCLCPhase 3Phase 3 trial is ongoing.\n\nResected adjuvant NSCLCPhase 3Phase 3 trial was initiated.\n\nUnresected adjuvant NSCLCPhase 3Phase 3 trial was initiated.\n\nSofetabart mipitecan (FRα ADC)(3)\n\nPlatinum-resistant ovarian cancerPhase 3Phase 3 trial was initiated.\n\n(1) Granted a Commissioner's National Priority Voucher from the FDA.\n\n(2) In collaboration with Almirall, S.A. in Europe.\n\n(3) The FDA granted Breakthrou
…[6741 more chars]
```

---
### LLM CALL #3  (seq 5)  actual prompt_tokens=8473 completion_tokens=523  -> gpt-5.4-mini-2026-03-17: 1 tool call
(assistant text alongside the tool calls is NOT persisted; only the tool calls below are)

#### LLM OUT -> GATE  seq 6  `respond`  recorded=error: relation_does_not_fit
LLM wrote (claims + prose, full):
```json
{
 "prose": [
  "I can’t forecast Lilly’s margins next year; by policy, a projected future margin is absent here rather than estimated {c1}.",
  "What the filing says moved profitability in 2025 was mainly higher gross margin, while marketing, selling, administrative, and R&D spending partly offset that {c3}.",
  "On the revenue side, the filing says 2025 growth came primarily from higher volume, partly offset by lower realized prices, with Mounjaro and Zepbound named as the main drivers {c2}.",
  "For next year, the filing points to the main things that could keep margins moving: pricing pressure from the November 2025 U.S. agreements and the broader pricing/reimbursement environment {c4}.",
  "It also says the IRA will continue to materially influence the business and could significantly affect results of operations {c5}.",
  "So the desk will not give you a margin forecast; the filing-backed reading is that margin expansion is possible only if gross margin stays ahead of pricing pressure and operating expenses do not outrun volume-led revenue growth."
 ],
 "claims": [
  {
   "id": "c1",
   "of": "f_7de4683d6b88",
   "relation": "absent"
  },
  {
   "id": "c2",
   "of": "f_7de4683d6b88",
   "span": "Revenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound.",
   "relation": "quote"
  },
  {
   "id": "c3",
   "of": "f_7de4683d6b88",
   "span": "Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.",
   "relation": "quote"
  },
  {
   "id": "c4",
   "of": "f_7de4683d6b88",
   "span": "In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations.",
   "relation": "quote"
  },
  {
   "id": "c5",
   "of": "f_7de4683d6b88",
   "span": "The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.",
   "relation": "quote"
  }
 ]
}
```
GATE input: ledger as of this step = 1 facts from completed steps with seq < 6
Facts each claim points at (from that ledger):
  - c1.of [absent] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c2.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c3.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c4.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c5.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
GATE VERDICT (replayed; this is the tool result the LLM read back):
```json
{
 "error": "relation_does_not_fit",
 "problems": [
  {
   "at": "c1",
   "relation": "absent",
   "reason": "kind_does_not_fit",
   "detail": "absent: f_7de4683d6b88 is a passage of a filing, which holds words and no figure — state it with relation 'quote' and the words verbatim in `span`; a figure from it is read with a program"
  }
 ],
 "detail": "a claim's relation must fit what its facts are: c1: kind_does_not_fit"
}
```

---
### LLM CALL #4  (seq 7)  actual prompt_tokens=9129 completion_tokens=504  -> gpt-5.4-mini-2026-03-17: 1 tool call
(assistant text alongside the tool calls is NOT persisted; only the tool calls below are)

#### LLM OUT -> GATE  seq 8  `respond`  recorded=keys: responded, format, blocks, text, citations, claims, verified
LLM wrote (claims + prose, full):
```json
{
 "prose": [
  "I can’t forecast Lilly’s margins next year; the desk does not forecast, and the filing itself flags Item 7 as forward-looking {c1}.",
  "The most relevant backward-looking clue is that 2025 net income improved mainly because gross margin was higher, while marketing, selling, administrative, and R&D expenses partly offset that {c2}.",
  "Revenue growth in 2025 was volume-led, with lower realized prices as the offset, especially from Mounjaro and Zepbound {c3}.",
  "For next year, the filing’s own margin headwinds are pricing pressure from the November 2025 U.S. agreements and the broader pricing/reimbursement environment {c4}.",
  "It also says the IRA will keep influencing strategy and could significantly impact results of operations {c5}.",
  "So my answer is not a number forecast: the filing points to continued support from volume and product mix, but margin expansion next year would depend on whether higher gross margin can outrun pricing concessions and operating expense growth."
 ],
 "claims": [
  {
   "id": "c1",
   "of": "f_7de4683d6b88",
   "span": "Certain statements in this Item 7 constitute forward-looking statements.",
   "relation": "quote"
  },
  {
   "id": "c2",
   "of": "f_7de4683d6b88",
   "span": "Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.",
   "relation": "quote"
  },
  {
   "id": "c3",
   "of": "f_7de4683d6b88",
   "span": "Revenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices.",
   "relation": "quote"
  },
  {
   "id": "c4",
   "of": "f_7de4683d6b88",
   "span": "In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations.",
   "relation": "quote"
  },
  {
   "id": "c5",
   "of": "f_7de4683d6b88",
   "span": "The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.",
   "relation": "quote"
  }
 ]
}
```
GATE input: ledger as of this step = 1 facts from completed steps with seq < 8
Facts each claim points at (from that ledger):
  - c1.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c2.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c3.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c4.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
  - c5.of [quote] -> f_7de4683d6b88 kind=passage measure=10-K Item 7 subject=LLY unit=None value=None as_of=n/a window=None params={'item': 'Item 7', 'title': "Management's Discussion and Analysis of Results of Operations and Financial Condition", 'accession': '0000059478-26-000013', 'form_type': '10-K'} text="Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition\n\n(Tables present dollars in millions, except per-share data, and numbers may not add due to rounding)\n\nGeneral\n\nManagement's discussion and analysis of results of operations and financial condition is intend"
GATE VERDICT (replayed): ACCEPTED   [replayed render == stored answer: True]
Prose-number resolution (G3), token -> facts it matched:
  prose[0] '7' (num) -> identity: f_7de4683d6b88=10-K Item 7/LLY/None@n/a
  prose[1] '2025' (num) -> passage: f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a
  prose[2] '2025' (num) -> passage: f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a
  prose[3] '2025' (num) -> passage: f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a; f_7de4683d6b88=10-K Item 7/LLY/None@n/a
READER SEES (claims.accepted -> answer.prose_of):
```
I can’t forecast Lilly’s margins next year; the desk does not forecast, and the filing itself flags Item 7 as forward-looking “Certain statements in this Item 7 constitute forward-looking statements.” [10-K Item 7].
The most relevant backward-looking clue is that 2025 net income improved mainly because gross margin was higher, while marketing, selling, administrative, and R&D expenses partly offset that “Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.” [10-K Item 7].
Revenue growth in 2025 was volume-led, with lower realized prices as the offset, especially from Mounjaro and Zepbound “Revenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices.” [10-K Item 7].
For next year, the filing’s own margin headwinds are pricing pressure from the November 2025 U.S. agreements and the broader pricing/reimbursement environment “In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations.” [10-K Item 7].
It also says the IRA will keep influencing strategy and could significantly impact results of operations “The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.” [10-K Item 7].
So my answer is not a number forecast: the filing points to continued support from volume and product mix, but margin expansion next year would depend on whether higher gross margin can outrun pricing concessions and operating expense growth.
```

## 2. Final stored assistant message
```
I can’t forecast Lilly’s margins next year; the desk does not forecast, and the filing itself flags Item 7 as forward-looking “Certain statements in this Item 7 constitute forward-looking statements.” [10-K Item 7].
The most relevant backward-looking clue is that 2025 net income improved mainly because gross margin was higher, while marketing, selling, administrative, and R&D expenses partly offset that “Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.” [10-K Item 7].
Revenue growth in 2025 was volume-led, with lower realized prices as the offset, especially from Mounjaro and Zepbound “Revenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices.” [10-K Item 7].
For next year, the filing’s own margin headwinds are pricing pressure from the November 2025 U.S. agreements and the broader pricing/reimbursement environment “In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations.” [10-K Item 7].
It also says the IRA will keep influencing strategy and could significantly impact results of operations “The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.” [10-K Item 7].
So my answer is not a number forecast: the filing points to continued support from volume and product mix, but margin expansion next year would depend on whether higher gross margin can outrun pricing concessions and operating expense growth.
```
meta: {
 "format": "blocks",
 "pushed": [
  "issuer_outlook_boundary",
  "issuer_profitability"
 ],
 "prompt_tokens": 9874
}